

Maurizia R Brunetto

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1612138/maurizia-r-brunetto-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186
papers

9,823
citations

49
h-index

96
g-index

217
ext. papers

11,514
ext. citations

5.4
avg, IF

5.44
L-index

#	Paper	IF	Citations
186	Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment.. <i>Frontiers in Oncology</i> , 2022 , 12, 822507	5.3	0
185	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 733-744	6.1	2
184	Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. <i>European Journal of Cancer</i> , 2021 , 158, 133-143	7.5	
183	A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. <i>Cancers</i> , 2021 , 13,	6.6	1
182	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. <i>PLoS ONE</i> , 2021 , 16, e0251552	3.7	1
181	Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021 , 41, 1713-1733	7.9	13
180	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021 , 160, 2483-2495.e26	13.3	9
179	Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. <i>Liver Cancer International</i> , 2021 , 2, 45-53	0.8	1
178	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 46-60.e8	6.9	15
177	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021 , 53, 612-619	3.3	3
176	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 12-19	3.4	12
175	The changing scenario of hepatocellular carcinoma in Italy: an update. <i>Liver International</i> , 2021 , 41, 585-597	7.9	25
174	A Deep Learning Approach for Hepatic Steatosis Estimation from Ultrasound Imaging. <i>Communications in Computer and Information Science</i> , 2021 , 703-714	0.3	
173	Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. <i>Liver Cancer</i> , 2021 , 10, 126-136	9.1	3
172	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021 , 13,	6.6	2
171	Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. <i>Cancers</i> , 2021 , 13,	6.6	4
170	Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2021 , 27, 4999-5018	5.6	1

169	Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. <i>Digestive and Liver Disease</i> , 2021 , 53, 1011-1019	3.3	6
168	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021 , 75, 572-581	13.4	8
167	Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. <i>Liver International</i> , 2021 ,	7.9	2
166	Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
165	Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?. <i>World Journal of Gastroenterology</i> , 2021 , 27, 5536-5554	5.6	3
164	The Role of Elastography in HBV: Assessing Liver Fibrosis 2021 , 43-59		
163	Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 1406-1416	6.1	3
162	Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. <i>Cancer Biomarkers</i> , 2020 , 29, 189-196	3.8	6
161	Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. <i>Journal of Hepatology</i> , 2020 , 73, 593-602	13.4	28
160	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020 , 72, 539-557	13.4	88
159	Urgent liver transplantation soon after recovery from COVID-19 in a patient with decompensated liver cirrhosis. <i>Hepatology Communications</i> , 2020 , 5, 144	6	12
158	An E-Nose for the Monitoring of Severe Liver Impairment: A Preliminary Study. <i>Sensors</i> , 2019 , 19,	3.8	5
157	Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. <i>Gastroenterology</i> , 2019 , 157, 227-241.e7	13.3	52
156	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019 , 71, 397-408	13.4	163
155	Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. <i>Current Medical Research and Opinion</i> , 2019 , 35, 661-666	2.5	1
154	Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019 , 9, 10529	4.9	7
153	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2019 , 71, 1070	11.2	23
152	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-128	5.38	5

151	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019 , 51, 310-317	3.3	29
150	ALSF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019 , 51, 10-23	3.3	4
149	Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 118-124	3.4	11
148	HBV pre-core mutant in genotype-D infected children is selected during HBeAg/anti-HBe seroconversion and leads to HBeAg negative chronic hepatitis B in adulthood. <i>Journal of Medical Virology</i> , 2018 , 90, 1232-1239	19.7	5
147	Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 911-919	3.4	7
146	TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)ide Analogues. <i>Gastroenterology</i> , 2018 , 154, 1764-1777.e7	13.3	87
145	96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018 , 68, 672-681	13.4	180
144	Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers. <i>Cancer Biomarkers</i> , 2018 , 21, 603-612	3.8	15
143	Steato-Score: Non-Invasive Quantitative Assessment of Liver Fat by Ultrasound Imaging. <i>Ultrasound in Medicine and Biology</i> , 2018 , 44, 1585-1596	3.5	8
142	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 383-403	18.8	702
141	Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. <i>Liver International</i> , 2018 , 38, 821-833	7.9	17
140	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
139	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , 2018 , 38, 2190-2198	7.9	23
138	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. <i>World Journal of Hepatology</i> , 2018 , 10, 231-245	3.4	9
137	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , 2018 , 31, 712-721	2.2	3
136	Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. <i>World Journal of Hepatology</i> , 2018 , 10, 409-416	3.4	2
135	Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2018 , 68, 431-440	13.4	98
134	IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB) 2018 ,		2

133	Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2018 ,	6.9	24
132	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. <i>PLoS ONE</i> , 2018 , 13, e0199198	3.7	4
131	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
130	Genome-Wide Comparison of Next-Generation Sequencing and qPCR Platforms for microRNA Profiling in Serum. <i>Methods in Molecular Biology</i> , 2017 , 1580, 21-44	1.4	11
129	Reply to: "Serum HBsAg kinetics in clinical prediction". <i>Journal of Hepatology</i> , 2017 , 67, 193-194	13.4	
128	Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance. <i>Liver International</i> , 2017 , 37, 1622-1631	7.9	26
127	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017 , 66, 1814-1825	11.2	18
126	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017 , 66, 398-411	13.4	191
125	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017 , 12, e0172159	3.7	31
124	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. <i>PLoS ONE</i> , 2017 , 12, e0185728	3.7	28
123	AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2016 , 48, 860-8	3.3	14
122	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3	12
121	New immunoassays for total, IgA and IgM antibodies against hepatitis E virus: Prevalence in Italian blood donors and patients with chronic liver or kidney diseases. <i>Digestive and Liver Disease</i> , 2016 , 48, 536-541	3.3	19
120	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1481-1489.e5	6.9	36
119	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 333-42	3.3	42
118	Modeling HCV Dynamics in Clinical Practice to Personalize Antiviral Therapy 2016 , 303-321		
117	Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 196-206	18.8	259
116	Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. <i>Journal of Hepatology</i> , 2015 , 63, 30-7	13.4	31

115	Reply to: "To target or not to target viral antigens in HBV related HCC?". <i>Journal of Hepatology</i> , 2015 , 62, 1450-2	13.4	3
114	Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy. <i>Thyroid</i> , 2015 , 25, 846-50	6.2	26
113	Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. <i>Journal of Hepatology</i> , 2015 , 62, 56-63	13.4	50
112	Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection. <i>Gastroenterology</i> , 2015 , 148, 355-366.e1	13.3	45
111	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naïve chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015 , 64, 948-56	19.2	90
110	Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. <i>BMJ, The</i> , 2015 , 350, h3363	5.9	4
109	Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease. <i>PLoS ONE</i> , 2015 , 10, e0130209	3.7	35
108	T cell receptor-therapy in HBV-related hepatocellularcarcinoma. <i>Oncolmmunology</i> , 2015 , 4, e1008354	7.2	27
107	Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials. <i>Digestive and Liver Disease</i> , 2015 , 47, 988-93	3.3	3
106	Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study. <i>European Journal of Endocrinology</i> , 2015 , 172, 269-76	6.5	45
105	Laparoscopic robot-assisted distal splenorenal shunt. <i>Surgery</i> , 2015 , 157, 405	3.6	3
104	Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. <i>Journal of Hepatology</i> , 2015 , 62, 486-91	13.4	123
103	A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015 , 47, 249-54	3.3	4
102	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). <i>Digestive and Liver Disease</i> , 2014 , 46, 18-24	3.3	9
101	Interferon therapy of chronic hepatitis B. <i>Intervirology</i> , 2014 , 57, 163-70	2.5	16
100	A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. <i>PLoS ONE</i> , 2014 , 9, e110782	3.7	29
99	Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. <i>Journal of Virological Methods</i> , 2013 , 189, 110-7	2.6	4
98	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. <i>Hepatology International</i> , 2013 , 7, 88-97	8.8	117

97	Occult Hepatitis B Virus (HBV) Infections: Hepatitis B Surface Antigen (HBsAg) Negative and Primary Occult. <i>Current Hepatitis Reports</i> , 2013 , 12, 112-118		
96	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. <i>Journal of Infection</i> , 2013 , 67, 322-8	18.9	23
95	Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. <i>Journal of Hepatology</i> , 2013 , 59, 1153-9	13.4	76
94	Impatto sul budget di un trattamento personalizzato dell'epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimana. <i>Pharmacoeconomics Italian Research Articles</i> , 2013 , 15, 123-130		
93	Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. <i>Antiviral Therapy</i> , 2013 , 18, 623-33	1.6	11
92	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , 2012 , 56, 1006-1011	13.4	133
91	HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. <i>Journal of Hepatology</i> , 2012 , 56, 1254-8	13.4	29
90	IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection. <i>Journal of Immunology</i> , 2012 , 189, 3925-35	5.3	254
89	Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs. <i>PLoS ONE</i> , 2012 , 7, e31952	3.52	51
88	Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy. <i>PLoS ONE</i> , 2012 , 7, e47715	3.7	48
87	Identification of new autoantigens by protein array indicates a role for IL4 neutralization in autoimmune hepatitis. <i>Molecular and Cellular Proteomics</i> , 2012 , 11, 1885-97	7.6	28
86	Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?. <i>Gut</i> , 2012 , 61, 641-5	19.2	58
85	Modeling the Dynamics of HCV Infected Cells to Tailor Antiviral Therapy in Clinical Practice: Can This Approach Fit for Neoplastic Cells?. <i>SIMA1 Springer Series</i> , 2012 , 329-336		
84	Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011 , 43, 259-65	3.3	25
83	Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). <i>Digestive and Liver Disease</i> , 2011 , 43, 589-95	3.3	39
82	Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. <i>Journal of Hepatology</i> , 2011 , 55, 1121-31	13.4	237
81	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010 , 42, 658-60	36.3	337
80	Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. <i>Journal of Vascular and Interventional Radiology</i> , 2010 , 21, 1533-8	2.4	28

79	Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. <i>Gastroenterology</i> , 2010 , 139, 483-90	13.3	296
78	A new role for an old marker, HBsAg. <i>Journal of Hepatology</i> , 2010 , 52, 475-7	13.4	94
77	Hepatitis B, C and Delta virus infections in Albanian patients with chronic liver disease: evaluation of possible changes during the last 10 years. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 167-71	2.2	6
76	Liver stiffness, a non-invasive marker of liver disease: a core study group report. <i>Antiviral Therapy</i> , 2010 , 15 Suppl 3, 69-78	1.6	28
75	Diagnostic markers of chronic hepatitis B infection and disease. <i>Antiviral Therapy</i> , 2010 , 15 Suppl 3, 35-44.6		17
74	The natural history of chronic HBV infection and geographical differences. <i>Antiviral Therapy</i> , 2010 , 15 Suppl 3, 25-33	1.6	101
73	New approaches to optimize treatment responses in chronic hepatitis B. <i>Antiviral Therapy</i> , 2010 , 15 Suppl 3, 61-8	1.6	7
72	In vitro liver model using microfabricated scaffolds in a modular bioreactor. <i>Biotechnology Journal</i> , 2010 , 5, 232-41	5.6	32
71	Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2009 , 49, 1141-50	11.2	359
70	Reply:. <i>Hepatology</i> , 2009 , 50, 1314-1314	11.2	1
69	Asymptomatic hyperamylasemia and hyperlipasemia associated with aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 504-6	1.7	3
68	Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis. <i>World Journal of Gastroenterology</i> , 2009 , 15, 531-7	5.6	16
67	Personalized therapy in chronic viral hepatitis. <i>Molecular Aspects of Medicine</i> , 2008 , 29, 103-11	16.7	2
66	Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. <i>Journal of Hepatology</i> , 2008 , 49, 217-22	13.4	87
65	A novel immunosuppressive strategy combined with preemptive antiviral therapy improves the eighteen-month mortality in HCV recipients transplanted with aged livers. <i>Transplantation</i> , 2008 , 86, 1666-71	1.8	20
64	Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. <i>World Journal of Gastroenterology</i> , 2008 , 14, 6154-62	5.6	104
63	Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. <i>Liver International</i> , 2007 , 27, 612-9	7.9	25
62	Thermal care of functional dyspepsia based on bicarbonate-sulphate-calcium water: a sequential clinical trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2007 , 4, 381-91	2.3	4

61	Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. <i>Journal of Experimental Medicine</i> , 2007 , 204, 667-80	16.6	335
60	Subthreshold mania as predictor of depression during interferon treatment in HCV+ patients without current or lifetime psychiatric disorders. <i>Journal of Psychosomatic Research</i> , 2007 , 62, 349-55	4.1	22
59	Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. <i>Hepatology</i> , 2006 , 43, 100-7	11.2	163
58	A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. <i>Antiviral Therapy</i> , 2006 , 11, 197-212	1.6	15
57	A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon-2A, Lamivudine and Combination Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 197-212	1.6	33
56	Software and expert system for the management of chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2005 , 34 Suppl 1, S29-33	14.5	1
55	Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. <i>Journal of Hepatology</i> , 2005 , 42, 61-7	13.4	92
54	Association of hepatitis C virus envelope proteins with exosomes. <i>European Journal of Immunology</i> , 2004 , 34, 2834-42	6.1	155
53	Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. <i>Thyroid</i> , 2004 , 14, 403-6	6.2	116
52	Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. <i>Journal of Medical Virology</i> , 2003 , 70, 27-30	19.7	42
51	Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. <i>Journal of Hepatology</i> , 2003 , 39 Suppl 1, S160-3	13.4	49
50	Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. <i>Journal of Hepatology</i> , 2003 , 39 Suppl 1, S164-7	13.4	25
49	Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. <i>Antiviral Therapy</i> , 2003 , 8, 519-30	1.6	11
48	Sustained Response to InterferonRibavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase. <i>Antiviral Therapy</i> , 2003 , 8, 519-530	1.6	25
47	Recent progress and new trends in the treatment of hepatitis B. <i>Journal of Medical Virology</i> , 2002 , 67, 458-62	19.7	16
46	Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. <i>Journal of Hepatology</i> , 2002 , 36, 263-70	13.4	257
45	Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy. <i>Expert Review of Molecular Diagnostics</i> , 2001 , 1, 310-4	3.8	
44	Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. <i>Hepatology</i> , 2000 , 32, 824-7	11.2	182

43	The impact of hepatitis B virus (HBV) and hepatitis C virus (HCV) : from research to clinical practice. <i>Methods in Molecular Medicine</i> , 2000 , 45, 99-112		
42	Hepatitis B virus mutants. <i>Intervirology</i> , 1999 , 42, 69-80	2.5	60
41	Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. <i>American Journal of Gastroenterology</i> , 1999 , 94, 1366-72	0.7	44
40	Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity?. <i>Hepatology</i> , 1999 , 29, 585-9	11.2	67
39	High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. <i>Journal of Hepatology</i> , 1999 , 31, 990-6	13.4	15
38	Long term response to therapy of chronic anti-HBe β positive Hepatitis B is poor independent of type and schedule of interferon. <i>American Journal of Gastroenterology</i> , 1999 , 94, 1366-1372	0.7	32
37	IgM antibody against measles virus in patients with inflammatory bowel disease: a marker of virus-related disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 1997 , 9, 661-3	2.2	14
36	The prevalence of hepatitis C virus types in patients of the same geographic area, according to the source of infection and liver disease. <i>Clinical and Diagnostic Virology</i> , 1997 , 8, 189-94		3
35	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997 , 51, 313-318	19.7	62
34	Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new "gray-zone" for the evaluation of "borderline" values. <i>Journal of Hepatology</i> , 1996 , 25, 644-8	13.4	34
33	High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders. <i>British Journal of Haematology</i> , 1996 , 95, 204-11	4.5	52
32	Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. <i>Liver</i> , 1994 , 14, 175-81		46
31	Precore mutant hepatitis B virus and outcome of chronic infection and hepatitis in hepatitis B e antigen-positive children. <i>Pediatric Research</i> , 1994 , 36, 347-50	3.2	14
30	Recombinant interferon- α hastens the rate of HBeAg clearance in children with chronic hepatitis B. <i>Hepatology</i> , 1994 , 20, 287-290	11.2	62
29	Hepatitis C virus infection and liver disease: peculiar epidemiological and clinicopathological features. <i>FEMS Microbiology Reviews</i> , 1994 , 14, 259-65	15.1	7
28	Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. <i>Journal of Hepatology</i> , 1994 , 21, 961-5	13.4	20
27	Asymptomatic anti-HCV seropositive subjects include patients with chronic active hepatitis and individuals with normal liver: can we distinguish them?. <i>Journal of Hepatology</i> , 1994 , 21, 136-7	13.4	4
26	Detection of hepatitis C virus RNA by reverse-transcriptase and polymerase chain reaction: clinical applications of quantitative analysis. <i>Clinical and Diagnostic Virology</i> , 1994 , 1, 289-97		12

25	Possible immunopathogenesis for fibrosing cholestatic hepatitis. <i>Gastroenterology</i> , 1994 , 106, 822-3	13.3	3
24	Hepatitis B Virus Precore Mutants 1994 , 256-260		1
23	Recombinant interferon- α hastens the rate of HBeAg clearance in children with chronic hepatitis B 1994 , 20, 287		9
22	Wild-type and HBeAg-minus HBV Fluctuations: Cause or Effect of Chronic Hepatitis B Pathogenic Mechanisms? 1994 , 261-264		
21	Clinical significance of the antibody to the putative core protein of hepatitis C virus in patients with chronic liver disease. <i>Liver</i> , 1993 , 13, 222-6		3
20	Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. <i>Journal of Hepatology</i> , 1993 , 18, 5-8	13.4	24
19	Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. <i>Journal of Hepatology</i> , 1993 , 19, 431-6	13.4	73
18	Hepatitis C virus infection and disease. Diagnostic problems. <i>Journal of Hepatology</i> , 1993 , 17 Suppl 3, S78-82	13.4	11
17	T-lymphocyte response to hepatitis C virus in different clinical courses of infection. <i>Gastroenterology</i> , 1993 , 104, 580-7	13.3	297
16	Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. <i>Gastroenterology</i> , 1993 , 105, 845-50	13.3	169
15	Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. <i>Virology</i> , 1993 , 194, 137-48	3.6	123
14	Role of hepatitis delta virus infection in hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 1991 , 36, 1134-6	4	52
13	Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. <i>Hepatology</i> , 1991 , 13, 413-416	11.2	78
12	Hepatitis delta virus, a model of liver cell pathology. <i>Journal of Hepatology</i> , 1991 , 13, 260-6	13.4	12
11	Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S102-4	13.4	43
10	Serological diagnosis of hepatitis B and delta virus (HBV/HDV) coinfection. <i>Journal of Hepatology</i> , 1991 , 12, 10-3	13.4	11
9	Sequence variation in hepatitis C viral isolates. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 4, S6-14	13.4	42
8	Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen. <i>Journal of Hepatology</i> , 1991 , 13 Suppl 1, S8-11	13.4	19

- 7 Diagnosis of Budd-Chiari syndrome by pulsed Doppler ultrasound. *Gastroenterology*, **1991**, 100, 1324-1331,3 72
- 6 Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D **1991**, 13, 413 6
- 5 A precore-defective mutant of hepatitis B virus associated with e antigen-negative chronic liver disease. *Journal of Medical Virology*, **1990**, 32, 109-18 19.7 49
- 4 Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. *Hepatology*, **1989**, 10, 198-202 11.2 204
- 3 Nucleic acid hybridization in viral hepatitis research. *Research in Clinic and Laboratory*, **1988**, 18, 121-42
- 2 The impact of molecular biology in the diagnosis and management of viral hepatitis. *Research in Clinic and Laboratory*, **1988**, 18, 261-71 1
- 1 Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen. *Journal of Hepatology*, **1988**, 7, 14-20 13.4 22